InsiderSignal.AI

InsiderSignal.ai

AMLX - Amylyx Pharmaceuticals, Inc.

Insider Sale by Cohen Joshua B (Co-CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Cohen Joshua B, serving as Co-CEO at Amylyx Pharmaceuticals, Inc. (AMLX), sold 29,282 shares at $14.48 per share, for a total transaction value of $424,120.00. Following this transaction, Cohen Joshua B now holds 3,334,683 shares of AMLX.

This sale represents a 1.00% decrease in Cohen Joshua B's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Amylyx Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Cohen Joshua B

Co-CEO

Joshua B. Cohen is the Co-Founder and Co-CEO of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases such as ALS.[[1]](https://2024.worldmedicalinnovation.org/speaker/joshua-cohen/)[[3]](https://www.amylyx.com/our-company/leadership-team)[[6]](https://www.amylyx.com/our-company) He co-founded the company in 2013 with Justin Klee while at Brown University, growing it from a dorm-room idea to a publicly traded entity with global operations in the US, Canada, and the Netherlands.[[1]](https://2024.worldmedicalinnovation.org/speaker/joshua-cohen/)[[2]](https://engineering.brown.edu/news/2021-06-30/josh-cohen-amylyx)[[5]](https://xtalks.com/the-road-ahead-for-former-als-hopeful-relyvrio-ft-amylyxs-joshua-cohen-and-justin-klee/) Cohen co-invented AMX0035 (Relyvrio/Albrioza), which received FDA and Health Canada approvals for ALS before being withdrawn following confirmatory trial data.[[1]](https://2024.worldmedicalinnovation.org/speaker/joshua-cohen/)[[5]](https://xtalks.com/the-road-ahead-for-former-als-hopeful-relyvrio-ft-amylyxs-joshua-cohen-and-justin-klee/) A National Merit Scholar, Cohen holds a Bachelor of Science in biomedical engineering from Brown University ('14), where he founded the Brown Biotechnology Investment Group and published research at NIST and in the *Journal of Pharmaceutical Sciences*.[[1]](https://2024.worldmedicalinnovation.org/speaker/joshua-cohen/)[[2]](https://engineering.brown.edu/news/2021-06-30/josh-cohen-amylyx) His career highlights include recognition on Business Insider’s 30 Under 40 in Healthcare (2020), PM360’s ELITE lists (2020, 2022), and awards like the Harvey and Bonny Gaffen Advancements in ALS Award (2022).[[1]](https://2024.worldmedicalinnovation.org/speaker/joshua-cohen/) Recently, as Co-CEO, he sold 7,715 shares of AMLX stock on January 6, 2026, at $11.09 per share.[[4]](https://www.marketbeat.com/instant-alerts/joshua-cohen-sells-7715-shares-of-amylyx-pharmaceuticals-nasdaqamlx-stock-2026-01-08/)

View full insider profile →

Trade Price

$14.48

Quantity

29,282

Total Value

$424,120.00

Shares Owned

3,334,683

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Amylyx Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning AMLX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4496384

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime